Answers are grounded in this paper and cite their sources.
Objectives: Immune checkpoint inhibitors (ICIs) have transformed the treatment of dMMR/MSI metastatic colorectal cancer (mCRC), whereas their value in the far more common pMMR/MSS phenotype remains unresolved because of its immune-cold biology. This systematic review and network meta-analysis evaluated the efficacy and safety of ICI-based combination strategies in pMMR/MSS mCRC. Methods: Six international and Chinese databases were searched for randomized trials and non-randomized studies. Thirteen studies with 2157 patients were included; the primary outcome was progression-free survival (PFS), and secondary outcomes were overall survival (OS), objective response rate (ORR) and treatment-related adverse events (TRAEs). Effects were synthesized with a frequentist random-effects network meta-analysis. Results: In the connected network (11 studies, 12 comparisons, 4 treatment nodes), ICI plus targeted therapy ranked first for PFS (HR 0.671, 95% CI 0.533–0.844 versus chemotherapy plus targeted therapy; P-score 0.881) and the triplet ICI + chemotherapy + targeted therapy was also associated with longer PFS (HR 0.772, 95% CI 0.621–0.961; P-score 0.549); between-study heterogeneity was moderate (I2 = 21.2%, tau2 = 0.0125, Q = 11.42, df = 9, p = 0.248), and the two ICI-containing strategies did not differ from each other (HR 1.151, 95% CI 0.839–1.581). Within the shared chemotherapy plus bevacizumab backbone, the first-line estimate (HR 0.76, 95% CI 0.59–0.97, three studies) did not differ from the later-line estimate (0.70, 0.51–0.95, two studies; p = 0.68 for the subgroup difference). The estimate was insensitive to how the LEAP-017 comparator arm was assigned (HR 0.671 versus 0.647 under the two codings) but remained significant in all 11 leave-one-out iterations. Because the OS and ORR contrasts were clinically non-comparable, they are reported study by study rather than as pooled treatment effects: only dual ICI plus best supportive care improved OS, and ORR was higher with ICI-containing regimens in nine of the fourteen study-level comparisons, lower in four and identical in one. Grade III-V TRAEs were, by contrast, more frequent with ICI-containing regimens in six of the seven study-level comparisons, with odds ratios from 1.25 to 7.12, the single exception being COLUMBIA-1, which counted treatment-emergent rather than treatment-related events. Conclusions: In pMMR/MSS mCRC, ICI-based combinations show a modest and imprecisely estimated PFS advantage, most evident for ICI plus targeted therapy, at the cost of increased severe toxicity. The direct evidence is narrow, the ranking is exploratory, and practice should not change until adequately powered, biomarker-stratified randomized trials are available.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: